

might saddle state Medicaid programs with steep costs. US is the only major health-care market remaining without any meaningful drug price controls -- increased risk for the sector once the Congress gets involved, especially if focused primarily on pricing.

Description	Trade Date	Quantity	Last Price ¹	Unit Cost	Market Value	Unrealized G/L
SANGAMO BIOSCIENCES	05/28/2013	50,000.00	\$ 19.80	\$ 8.44	\$ 990,000.00	\$ 567,786.00
BIOGEN	02/14/2012	2,095.00	\$ 312.60	\$ 119.55	\$ 654,897.00	\$ 404,442.05
FOUNDATION MEDICINE	01/13/2014	25,000.00	\$ 36.40	\$ 27.51	910,000.00	\$ 222,336.50
GILEAD SCIENCES INC	2/5/14, 3/7/14	8,100.00	\$ 72.13	\$ 79.41	\$ 584,253.00	\$ (58,951.00)
ARIAD PHARMACEUTICALS	2/14/12, 1/24/13	16,535.00	\$ 7.60	\$ 17.60	\$ 125,666.00	\$ (165,331.40)
				Total Biotech	\$3,264,816.00	\$ 970,282.15

Nasdaq Biotech Index - 1yr Price History



Ariad - 1yr Price History